| abstract |
The invention relates to novel 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactones of general formula (I), where Z = O, H<SUB>2</SUB>, =NOR or =NNHSO<SUB>2</SUB>R, where R = H, a straight- or branched-chain 1-4 or 3-4 C alkyl group, R<SUP>4</SUP> = H, halogen, methyl or trifluoromethyl, R<SUP>6</SUP> and/or R<SUP>7</SUP> can be a- or ß-positioned and independently = branched- or straight-chain 1-4 or 3-4 alkyl, or R<SUP>6</SUP> = H and R<SUP>7</SUP> = a- or ß-positioned, straight- or branched-chain 1-4 or 3-4 C alkyl, or R<SUP>6</SUP> and R<SUP>7</SUP> = H, or R<SUP>6</SUP> and R<SUP>7</SUP> together = a- or ß-positioned methylene or an additional bond. The novel compounds have gestagenic and antimineralocorticoid activity and are suitable for the production of pharmaceutical preparations, for example, for oral contraception and the treatment of pre-, peri- and post-menopausal pain. |